Background: We derived a new equation to include interferon-c (IFN-c) levels in the QuantiFERON-Gold In-Tube (QFT-GIT) assay to discriminate active tuberculosis (ATB) infection from latent TB, and compared the diagnostic performance of the QFT-GIT assay and the new equation.
The global burden of tuberculosis (TB) is enormous despite advances in diagnosis and treatment. The prevalence of TB has decreased since the year 2000. Despite this fact, the World Health Organization (WHO) estimates the worldwide prevalence of TB to be 9.6 million, resulting in 1.5 million TBrelated deaths in 2014. 1 The incidence of TB in South Korea has declined with economic growth and healthcare improvement; however, 86 TB cases occurred per 100,000 individuals in the year 2014, affecting a total of 43,000 people. 1 TB infection mostly occurs through inhalation of droplets containing Mycobacterium tuberculosis (MTB), which are released by patients with active TB. The innate immune system response without activation of T-lymphocytes is responsible for eliminating MTB in approximately half of exposed individuals; in these individuals, the tuberculin skin test and interferon-c release assay (IGRA) results are negative. The remaining individuals show positive results in the tuberculin skin test and IGRA, of which 95% progress to latent infection and 5% to active infection. 2, 3 Although the proportion of those proceeding to active TB infection (ATB) is small, these individuals represent a strong infection source. Thus, timely and accurate diagnosis of ATB is critical.
Abbreviations TB, tuberculosis; WHO, World Health Organization; MTB, Mycobacterium tuberculosis; IGRA, interferon-c release assay; ATB, active TB infection; AFB, acid-fast bacilli; QFT-GIT, QuantiFERON TB Gold In-Tube; IFN-c, interferon-c; TBAg, TB-specific antigen; PCR, polymerase chain reaction; HIV, human immunodeficiency virus; HTN, hypertension; DM, diabetes mellitus; WBC, white blood cell; CRP, C-reactive protein; ESAT-6, 6 kDa early secretory antigenic target; CFP-10, 10 kDa culture filtrate antigen; AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value; FN, false-negative; FP, false-positive; CI, confidence interval; IL, interleukin; CVD, cardiovascular disease; CeVD, cerebrovascular disease Diagnosis of ATB is based on clinical symptoms, chest X-ray results, and the results of molecular genetic analyses in some cases; however, it is essential that acid-fast bacilli (AFB) staining and mycobacterial culture are conducted. Limitations to AFB staining include lower sensitivity compared with culture and the fact that the quality of the specimen (eg, sputum) must be determined. Also, mycobacterial culture as a confirmatory method for ATB requires a prolonged period of 6 weeks to 8 weeks or at least 1 to 2 weeks of liquid culture. Molecular genetic tests such as nucleic acid amplification must be performed to confirm the result when a specimen with negative results via smear yields a positive result via culture; a negative result via smear does not rule out diagnosis of pulmonary TB. 4 The QuantiFERON TB Gold In-Tube (QFT-GIT; Quest Diagnostics, Inc), a commercially available IGRA, may replace time-consuming conventional methods, producing results within 24 hours of the time that blood is drawn from patients. The assay measures interferon-c (IFN-c) after T-cell stimulation by an MTB-specific antigen in a TB-specific antigen (TBAg) tube, which is compared with each IFN-c value in a mitogen tube (positive control) and a nil tube (negative control).
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Numerous studies have applied IGRAs such as QFT-GIT for their time-saving advantage; however, only QFT-GIT is insufficient for discriminating ATB from latent TB. 6, 7 Some researchers [8] [9] [10] have suggested considering higher levels of IFN-c to TBAg in the tube or in a mitogen tube as alternative markers for ATB. Several clinical trials have been conducted to improve diagnostic performance by combining IFN-c with other cytokines. 11, 12 Despite these efforts, a definite marker for ATB has not been identified, to our knowledge.
In this study, we used an equation derived from the statistical analysis of individual IFN-c levels in nil, mitogen, and TBAg tubes used with the QFT-GIT assay to discriminate ATB from latent TB. Also, the diagnostic performance of QFT-GIT by itself and the equation were compared and analyzed.
Materials and Methods

Study Population and Data Assessment
A total of 567 patients with available QFT-GIT results and additional TB test results that detected the presence of ATB were enrolled retrospectively in our study from January 2013 
QFT-GIT Assay
We performed the QFT-GIT assay according to the manufacturer-provided instructions (Cellestis, Inc). Briefly, 1 mL of whole blood was collected into 3 different tubes; nil (negative control), mitogen (positive control), and TBAg tubes (MTB-specific antigens 6 kDa early secretory antigenic target [ESAT-6], 10 kDa culture filtrate antigen [CFP-10], and TB7.7). These 3 tubes were gently shaken to mix the contents and then incubated for 20 hours at 37 � C. We 
Statistical Analysis
We divided the overall population into ATB and non-ATB groups. These 2 groups were compared for respective demographic characteristics, laboratory results, and IFN-c data from QFT-GIT by performing the Mann-Whitney U or v 2 test.
We analyzed the diagnostic performance of QFT-GIT for ATB based on the manufacturer-provided interpretation criteria.
The equation to distinguish the ATB group from the non-ATB group in the overall population (n ¼ 567) was derived through discriminant analysis. Each IFN-c data point (obtained from nil, TBAg, TBAg-nil, mitogen, and mitogen-nil tubes) was used as independent variables for multivariate discriminant analysis for its relationship to ATB. Also, the clinical parameters of age, sex, CRP, and lymphocyte count were added to the multivariate discriminant analysis. We added each variable individually, using the simultaneous-input and staged-input methods, selecting the optimal equation with the highest rate of correctly classified cases and higher sensitivity for ATB. We analyzed the area under the curve (AUC) of the newly derived equation for diagnosing ATB and determined the optimal cut-off value at levels at which high sensitivity and specificity were maintained and the best diagnostic performance was observed. All statistical analyses were conducted using SPSS software (version 20; SPSS Inc); P<.05 indicated statistical significance.
Results
Demographic and Clinical Characteristics of the Study Population The prevalence of DM, HTN, cerebrovascular disease, and malignant neoplasms in the non-ATB group was higher than in the ATB groups. It is likely that these results are related to the older age of the non-ATB group. The percentage of patients with a history of smoking was similar between the 2 groups. Regarding laboratory data, WBC and neutrophil counts were higher in the non-ATB group (P <.001 and P <.002, respectively). CRP values in the non-ATB group were higher than in the ATB group, although the difference was not statistically significant. Markers of infection in the non-ATB group may have been higher because more than 40% of the non-ATB group had had pneumonia.
Comparison of IFN-c Values Obtained From
QFT-GIT Assay and the Newly Derived Z Equation, Between ATB and Non-ATB Groups Table 2 shows the results of comparisons between the ATB and non-ATB groups. We compared each IFN-c value (nil, In discriminant analysis, IFN-c levels from the nil and TBAg tubes were selected for multivariate discriminant analysis, based on the Wilks Lambda 
Diagnostic Performance of QFT-GIT Assay and the Newly Derived Z Equation for ATB Diagnosis
As shown in Table 3 , the sensitivity and specificity of QFT-GIT testing for the diagnosis of ATB were 90.6% and 63.0%, respectively. The positive predictive value (PPV) and negative predictive value (NPV) of the QFT-GIT were 48.8% and 94.5%, respectively. Despite the diagnosis of ATB, 9.4% (15/159) of patients with ATB showed false-negative (FN) 
Discussion
A systemic review and meta-analysis 13 reported that the sensitivity and specificity of the QFT-GIT assay for active pulmonary TB were 69% (95% confidence interval [CI], 52% to 83%) and 52% (95% CI, 41% to 63%), respectively, in patients with suspected TB. A low PPV can be problematic when QFT-GIT is performed for ATB diagnosis as a serologic test in meta-analysis. 14 Several previous cross-sectional studies for QFT-GIT in the diagnosis of ATB demonstrated low PPVs of 40% to 55%. 10, 15 The QFT-GIT result for the diagnosis of ATB also showed low PPV (48.8%) in this study and revealed unsatisfactory performance, although its sensitivity and specificity for ATB were high, at 90.6% and 63.0%, respectively.
Several studies have focused on the amount of released IFN-c in response to TBAg stimulation rather than on QFT-GIT results. IFN-c values in patients with ATB when stimulated with TBAg were significantly higher than in patients with latent TB. 9, 16 The odds of ATB increased 7% for each doubling of the IFN-c value. 17 In particular, the IFN-c value in response to TBAg stimulation generally increased according to bacilli loads. 18 In this study, the IFN-c levels from the nil tube and the TBAg tube contents, collected from patients with ATB, were also significantly higher than from patients without ATB. However, there was no definitive cutoff value of TBAg-induced IFN-c level to discriminate between ATB and latent TB. The ranges widely overlapped between ATB and latent TB. ATB cannot be diagnosed based on the QFT-GIT result only as interpreted by the manufacturerprovided criteria or by each IFN-c level measured under different conditions in the QFT-GIT assay. There were many causes of variable results of each IFN-c level in QFT-GIT, such as blood volume, shaking of blood tubes, transportation temperature, incubation delay, or incubation time. For these reasons, the reproducibility of QFT-GIT results can be low, which may lead to confusion in interpretation. 19, 20 Therefore, we derived an equation from discriminant analysis using variables with each IFN-c level for nil, TBAg, TBAg-nil, mitogen, or mitogen-nil tubes in the QFT-GIT assay. We processed the results of our discriminant analysis using variables of IFN-c for the nil and TBAg tubes, which showed significantly different values between ATB and non-ATB groups. However, the performance of the equation through discriminant analysis was not better, compared with that of the QFT-GIT assay; the sensitivity of the equation was decreased and the specificity increased. Also, the Z equation by itself cannot be used for the accurate diagnosis of ATB.
The practice of discriminating ATB from latent TB by using only the IFN-c level showed some limitations. Although different subpopulations of T cells were observed according to latent TB and ATB, the discrimination of these 2 disease states remains challenging because all cells secreted IFN-c with wide range. 21, 22 In previous studies and the present study, there was wide overlap in IFN-c levels between latent TB and ATB, despite higher IFN-c levels in subjects with ATB than in those with latent TB. [8] [9] [10] Therefore, when the prevalence of latent TB is high, differential diagnosis of ATB from latent TB is difficult using only IFN-c because the FP rate is increased.
To overcome nondiscriminations between ATB and latent TB, several studies have examined additional markers such as interleukin (IL)-2, IL-10, IL-13, and IFN-c inducible protein 10 to discriminate ATB from latent TB using the QFT-GIT settings. 23, 24 The ratio of IL-2 to IFN-c levels was significantly different between ATB and latent TB. 23 The ratio of TBAg to mitogen-induced IP-10 showed a discriminating power of ATB from latent TB. 22 However, because of the small number of subjects in previous studies, additional studies including larger populations are required to confirm these findings. Further, improved outcomes are expected for discriminant analysis when IFN-c and other markers are used.
A unique point of this study was the use of the actual value of IFN-c. We used the actual IFN-c values calculated from a standard curve for each batch of tests. QFT-GIT software provides interpretation with each IFN-c value from the nil, TBAg, TBAg-nil, mitogen, and mitogen-nil tubes. The IFN-c values are indicated as 10 (IU/mL) (500 pg/mL) in individuals undergoing treatment; however, the actual value can be 10 (IU/mL) (500 pg/mL) or greater. Most previous studies including treated individuals have been based on the data provided by this software. Few studies reported that the IFN-c of mitogen was low in ATB groups compared with than in non-ATB groups. 10, 25 However, IFN-c levels from mitogen or mitogen-nil tubes showed no differences in all patients vs in patients with positive QFT-GIT results in this study. This difference may be attributed to the use of the value '10' for treated individual values. There are several limitations in evaluating the diagnostic performance of QFT-GIT and the equation. The crosssectional design of this study could not reflect longitudinal results though long-term follow-up. Moreover, we did not consider other factors that may have influenced the results of this study, such as age, although older patients generally had a greater number of opportunities to be exposed to TB and showed high FP rates in this study.
Conclusions
In this study, we attempted to discriminate ATB from non-ATB in patients suspected of having TB by using discriminant analysis with each IFN-c value obtained from the QFT-GIT assay. The diagnostic performance of the equation derived from the overall population did not show better performance than that by QFT-GIT only. When using IFN-c by itself without other cytokines, the equation derived from each IFN-c value in the QFT-GIT test, along with QFT-GIT by itself, could not discriminate ATB from latent TB. A larger-scale study with additional markers is required to obtain better diagnostic performance for ATB. LM
